Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price traded down 5.2% during trading on Wednesday . The stock traded as low as C$1.46 and last traded at C$1.47. 57,476 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 73,669 shares. The stock had previously closed at C$1.55.
Cardiol Therapeutics Stock Up 7.4%
The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The company has a fifty day simple moving average of C$1.45 and a 200 day simple moving average of C$1.76. The firm has a market capitalization of C$132.77 million, a P/E ratio of -3.14 and a beta of 0.70.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
